Clinical Research Directory

Inclusion Criteria: * Subjects will be healthy and of any sex, any ethnicity, and any age from 50 to 80 * "Healthy" subjects will be defined as a real-world cohort of individuals likely to utilize such an intervention * May be on other medications if they do not conflict with rapamycin. * All medical conditions need to be stable and well controlled. * Willing and able to provide informed consent Exclusion Criteria: * Severe illnesses, for which rapamycin may cause harm. This would not be limited to but include active neoplastic or auto-immune disease. If patients have a previous history of cancer or auto-immune disease, the risks and benefits and possible adverse reactions will be discussed at time of consent * History of organ transplant * Any unstable medical condition that would interfere with the study * Hepatic impairment. Note: Patients with elevated liver enzymes and low albumin, will be further screened for hepatic impairment. Elevated liver enzymes \< 2x upper limit of normal will not be considered hepatic impairment. * Renal impairment, indicated by a serum creatinine \> 1.4 mg/dL * Anemia indicated by a hemoglobin \< 12 g/dL * Platelets \< 80,000/cumm, * ANC \< 1,000 / cumm * Total WBC \< 3,000/cumm * Pregnancy or breastfeeding or woman of childbearing potential with inadequate contraception * Unstable mental illness * A condition where rapamycin may interfere deleteriously with a medication that is taken by a potential subject * Currently prescribed with high dose CYP3A4 pathway medications such as verapamil \> 240 mg; simvastatin \>40 mg, lovastatin \> 40 mg or atorvastatin \> 40 mg daily. Poor GI motility as demonstrated by delayed gastric emptying on a radionucleotide isotope scan. * Intercurrent severe infection at initiation of study drug * Any and all other reasons that the investigator may determine that the participant is not suitable for study enrollment. * History of or active eating disorders as deemed by PI. * BMI lower than 18.5 * Any medication that may dangerously lower glucose while on the FMD. This will include insulin, sulfonylureas (glyburide; glipizide); Thiazolidenediones ( eg piogltazone; rosiglitazone); GLP1 drugs (semaglutide; tirzepatide);; DPP-4 inhibitors (eg sitagliptin; saxagliptin); Alpha -glucosidase inhibitors (acarbose; miglitol). Patients on SGLT2 inhibitors (empagliflozin; canagliflozin) and Metformin (glucophage) may be included in the study.